Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2003 Sep;62(9):799–804. doi: 10.1136/ard.62.9.799

Treatment of severe proliferative lupus nephritis: the current state

C Mok 1, R Wong 1, K Lai 1
PMCID: PMC1754677  PMID: 12922948

Full Text

The Full Text of this article is available as a PDF (120.4 KB).

Figure 1.

Figure 1

Open in a new tab

Treatment algorithm for severe proliferative lupus nephritis *Previous serious toxicities to CYC, severe cytopenia, patient's reluctance, etc. †Alternative treatments: MMF, CSA, immunoadsorption, apheresis, rituximab, IVIg.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alarcón-Segovia Donato, Tumlin James A., Furie Richard A., McKay James D., Cardiel Mario H., Strand Vibeke, Bagin Robert G., Linnik Matthew D., Hepburn Bonnie, LJP 394 Investigator Consortium LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2003 Feb;48(2):442–454. doi: 10.1002/art.10763. [DOI] [PubMed] [Google Scholar]
  2. Austin H. A., 3rd, Klippel J. H., Balow J. E., le Riche N. G., Steinberg A. D., Plotz P. H., Decker J. L. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986 Mar 6;314(10):614–619. doi: 10.1056/NEJM198603063141004. [DOI] [PubMed] [Google Scholar]
  3. Bakir A. A., Levy P. S., Dunea G. The prognosis of lupus nephritis in African-Americans: a retrospective analysis. Am J Kidney Dis. 1994 Aug;24(2):159–171. doi: 10.1016/s0272-6386(12)80177-6. [DOI] [PubMed] [Google Scholar]
  4. Bansal V. K., Beto J. A. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis. 1997 Feb;29(2):193–199. doi: 10.1016/s0272-6386(97)90029-9. [DOI] [PubMed] [Google Scholar]
  5. Belmont H. M., Storch M., Buyon J., Abramson S. New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis. Lupus. 1995 Apr;4(2):104–108. doi: 10.1177/096120339500400205. [DOI] [PubMed] [Google Scholar]
  6. Boletis J. N., Ioannidis J. P., Boki K. A., Moutsopoulos H. M. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet. 1999 Aug 14;354(9178):569–570. doi: 10.1016/S0140-6736(99)01575-5. [DOI] [PubMed] [Google Scholar]
  7. Boumpas D. T., Austin H. A., 3rd, Vaughan E. M., Yarboro C. H., Klippel J. H., Balow J. E. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med. 1993 Sep 1;119(5):366–369. doi: 10.7326/0003-4819-119-5-199309010-00003. [DOI] [PubMed] [Google Scholar]
  8. Boumpas D. T., Austin H. A., 3rd, Vaughn E. M., Klippel J. H., Steinberg A. D., Yarboro C. H., Balow J. E. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992 Sep 26;340(8822):741–745. doi: 10.1016/0140-6736(92)92292-n. [DOI] [PubMed] [Google Scholar]
  9. Boumpas D. T., Tassiulas I. O., Fleisher T. A., Vaughan E., Piscitelli S., Kim Y., Pucino F., Balow J. E., Austin H. A. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy. Clin Nephrol. 1999 Aug;52(2):67–75. [PubMed] [Google Scholar]
  10. Braun N., Erley C., Klein R., Kötter I., Saal J., Risler T. Immunoadsorption onto protein A induces remission in severe systemic lupus erythematosus. Nephrol Dial Transplant. 2000 Sep;15(9):1367–1372. doi: 10.1093/ndt/15.9.1367. [DOI] [PubMed] [Google Scholar]
  11. Brodsky R. A., Petri M., Smith B. D., Seifter E. J., Spivak J. L., Styler M., Dang C. V., Brodsky I., Jones R. J. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med. 1998 Dec 15;129(12):1031–1035. doi: 10.7326/0003-4819-129-12-199812150-00007. [DOI] [PubMed] [Google Scholar]
  12. Buratti S., Szer I. S., Spencer C. H., Bartosh S., Reiff A. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol. 2001 Sep;28(9):2103–2108. [PubMed] [Google Scholar]
  13. Cameron J. S. Lupus nephritis. J Am Soc Nephrol. 1999 Feb;10(2):413–424. doi: 10.1681/ASN.V102413. [DOI] [PubMed] [Google Scholar]
  14. Chan T. M., Li F. K., Tang C. S., Wong R. W., Fang G. X., Ji Y. L., Lau C. S., Wong A. K., Tong M. K., Chan K. W. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000 Oct 19;343(16):1156–1162. doi: 10.1056/NEJM200010193431604. [DOI] [PubMed] [Google Scholar]
  15. Chan T. M., Li F. K., Wong R. W., Wong K. L., Chan K. W., Cheng I. K. Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Nephron. 1995;71(3):321–327. doi: 10.1159/000188739. [DOI] [PubMed] [Google Scholar]
  16. Ciruelo E., de la Cruz J., López I., Gómez-Reino J. J. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum. 1996 Dec;39(12):2028–2034. doi: 10.1002/art.1780391212. [DOI] [PubMed] [Google Scholar]
  17. Clark W. F., Moist L. M. Management of chronic renal insufficiency in lupus nephritis: role of proteinuria, hypertension and dyslipidemia in the progression of renal disease. Lupus. 1998;7(9):649–653. doi: 10.1191/096120398678920802. [DOI] [PubMed] [Google Scholar]
  18. Conlon P. J., Fischer C. A., Levesque M. C., Smith S. R., St Clair E. W., Allen N. B., Fleming J. A., Howell D. N. Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis. Clin Nephrol. 1996 Sep;46(3):170–175. [PubMed] [Google Scholar]
  19. Daikh D. I., Finck B. K., Linsley P. S., Hollenbaugh D., Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol. 1997 Oct 1;159(7):3104–3108. [PubMed] [Google Scholar]
  20. Daikh D. I., Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol. 2001 Mar 1;166(5):2913–2916. doi: 10.4049/jimmunol.166.5.2913. [DOI] [PubMed] [Google Scholar]
  21. Danieli Maria Giovanna, Palmieri Carla, Salvi Aldo, Refe Maria Cristina, Strusi Anna Stella, Danieli Giovanni. Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis. J Clin Apher. 2002;17(2):72–77. doi: 10.1002/jca.10020. [DOI] [PubMed] [Google Scholar]
  22. Davis J. C., Jr, Austin H., 3rd, Boumpas D., Fleisher T. A., Yarboro C., Larson A., Balow J., Klippel J. H., Scott D. A pilot study of 2-chloro-2'-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis. Arthritis Rheum. 1998 Feb;41(2):335–343. doi: 10.1002/1529-0131(199802)41:2<335::AID-ART18>3.0.CO;2-O. [DOI] [PubMed] [Google Scholar]
  23. Davis J. C., Jr, Totoritis M. C., Rosenberg J., Sklenar T. A., Wofsy D. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol. 2001 Jan;28(1):95–101. [PubMed] [Google Scholar]
  24. Dinant H. J., Decker J. L., Klippel J. H., Balow J. E., Plotz P. H., Steinberg A. D. Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis. Ann Intern Med. 1982 Jun;96(6 Pt 1):728–736. doi: 10.7326/0003-4819-96-6-728. [DOI] [PubMed] [Google Scholar]
  25. Donadio J. V., Jr, Holley K. E., Ferguson R. H., Ilstrup D. M. Progressive lupus glomerulonephritis. Treatment with prednisone and combined prednisone and cyclophosphamide. Mayo Clin Proc. 1976 Aug;51(8):484–494. [PubMed] [Google Scholar]
  26. Donadio J. V., Jr, Holley K. E., Ferguson R. H., Ilstrup D. M. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med. 1978 Nov 23;299(21):1151–1155. doi: 10.1056/NEJM197811232992102. [DOI] [PubMed] [Google Scholar]
  27. Dooley M. A., Hogan S., Jennette C., Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int. 1997 Apr;51(4):1188–1195. doi: 10.1038/ki.1997.162. [DOI] [PubMed] [Google Scholar]
  28. Euler H. H., Schroeder J. O., Harten P., Zeuner R. A., Gutschmidt H. J. Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum. 1994 Dec;37(12):1784–1794. doi: 10.1002/art.1780371212. [DOI] [PubMed] [Google Scholar]
  29. Favre H., Miescher P. A., Huang Y. P., Chatelanat F., Mihatsch M. J. Ciclosporin in the treatment of lupus nephritis. Am J Nephrol. 1989;9 (Suppl 1):57–60. doi: 10.1159/000168040. [DOI] [PubMed] [Google Scholar]
  30. Felson D. T., Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med. 1984 Dec 13;311(24):1528–1533. doi: 10.1056/NEJM198412133112402. [DOI] [PubMed] [Google Scholar]
  31. Finck B. K., Linsley P. S., Wofsy D. Treatment of murine lupus with CTLA4Ig. Science. 1994 Aug 26;265(5176):1225–1227. doi: 10.1126/science.7520604. [DOI] [PubMed] [Google Scholar]
  32. Fu L. W., Yang L. Y., Chen W. P., Lin C. Y. Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria. Br J Rheumatol. 1998 Feb;37(2):217–221. doi: 10.1093/rheumatology/37.2.217. [DOI] [PubMed] [Google Scholar]
  33. Furie R. A., Cash J. M., Cronin M. E., Katz R. S., Weisman M. H., Aranow C., Liebling M. R., Hudson N. P., Berner C. M., Coutts S. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol. 2001 Feb;28(2):257–265. [PubMed] [Google Scholar]
  34. Geddes C. C., Cattran D. C. The treatment of idiopathic membranous nephropathy. Semin Nephrol. 2000 May;20(3):299–308. [PubMed] [Google Scholar]
  35. Gescuk Bryan D., Davis John C., Jr Novel therapeutic agents for systemic lupus erythematosus. Curr Opin Rheumatol. 2002 Sep;14(5):515–521. doi: 10.1097/00002281-200209000-00006. [DOI] [PubMed] [Google Scholar]
  36. Ginzler E., Diamond H., Guttadauria M., Kaplan D. Prednisone and azathioprine compared to prednisone plus low-dose azathioprine and cyclophosphamide in the treatment of diffuse lupus nephritis. Arthritis Rheum. 1976 Jul-Aug;19(4):693–699. doi: 10.1002/1529-0131(197607/08)19:4<693::aid-art1780190406>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  37. Gourley M. F., Austin H. A., 3rd, Scott D., Yarboro C. H., Vaughan E. M., Muir J., Boumpas D. T., Klippel J. H., Balow J. E., Steinberg A. D. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996 Oct 1;125(7):549–557. doi: 10.7326/0003-4819-125-7-199610010-00003. [DOI] [PubMed] [Google Scholar]
  38. Herlitz H., Edenö C., Mulec H., Westberg G., Aurell M. Captopril treatment of hypertension and renal failure in systemic lupus erythematosus. Nephron. 1984;38(4):253–256. doi: 10.1159/000183318. [DOI] [PubMed] [Google Scholar]
  39. Houssiau Frédéric A., Jadoul Michel. Cytotoxic therapy of lupus nephritis: recent developments. Nephrol Dial Transplant. 2002 Jun;17(6):955–957. doi: 10.1093/ndt/17.6.955. [DOI] [PubMed] [Google Scholar]
  40. Houssiau Frédéric A., Vasconcelos Carlos, D'Cruz David, Sebastiani Gian Domenico, Garrido Ed Enrique de Ramon, Danieli Maria Giovanna, Abramovicz Daniel, Blockmans Daniel, Mathieu Alessandro, Direskeneli Haner. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002 Aug;46(8):2121–2131. doi: 10.1002/art.10461. [DOI] [PubMed] [Google Scholar]
  41. Illei G. G., Austin H. A., Crane M., Collins L., Gourley M. F., Yarboro C. H., Vaughan E. M., Kuroiwa T., Danning C. L., Steinberg A. D. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001 Aug 21;135(4):248–257. doi: 10.7326/0003-4819-135-4-200108210-00009. [DOI] [PubMed] [Google Scholar]
  42. Illei G. G., Takada K., Parkin D., Austin H. A., Crane M., Yarboro C. H., Vaughan E. M., Kuroiwa T., Danning C. L., Pando J. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 2002 Apr;46(4):995–1002. doi: 10.1002/art.10142. [DOI] [PubMed] [Google Scholar]
  43. Ioannidis J. P., Boki K. A., Katsorida M. E., Drosos A. A., Skopouli F. N., Boletis J. N., Moutsopoulos H. M. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int. 2000 Jan;57(1):258–264. doi: 10.1046/j.1523-1755.2000.00832.x. [DOI] [PubMed] [Google Scholar]
  44. Jones D. S., Barstad P. A., Feild M. J., Hachmann J. P., Hayag M. S., Hill K. W., Iverson G. M., Livingston D. A., Palanki M. S., Tibbetts A. R. Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis. J Med Chem. 1995 Jun 9;38(12):2138–2144. doi: 10.1021/jm00012a013. [DOI] [PubMed] [Google Scholar]
  45. Kalunian Kenneth C., Davis John C., Jr, Merrill Joan T., Totoritis Mark C., Wofsy David, IDEC-131 Lupus Study Group Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Dec;46(12):3251–3258. doi: 10.1002/art.10681. [DOI] [PubMed] [Google Scholar]
  46. Karim M. Y., Alba P., Cuadrado M-J, Abbs I. C., D'Cruz D. P., Khamashta M. A., Hughes G. R. V. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 2002 Aug;41(8):876–882. doi: 10.1093/rheumatology/41.8.876. [DOI] [PubMed] [Google Scholar]
  47. Kingdon E. J., McLean A. G., Psimenou E., Davenport A., Powis S. H., Sweny P., Burns A. The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus. 2001;10(9):606–611. doi: 10.1191/096120301682430186. [DOI] [PubMed] [Google Scholar]
  48. Korbet S. M., Lewis E. J., Schwartz M. M., Reichlin M., Evans J., Rohde R. D. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis. 2000 May;35(5):904–914. doi: 10.1016/s0272-6386(00)70262-9. [DOI] [PubMed] [Google Scholar]
  49. Leandro Maria J., Edwards Jonathan C., Cambridge Geraldine, Ehrenstein Michael R., Isenberg David A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002 Oct;46(10):2673–2677. doi: 10.1002/art.10541. [DOI] [PubMed] [Google Scholar]
  50. Levy Y., Sherer Y., George J., Rovensky J., Lukac J., Rauova L., Poprac P., Langevitz P., Fabbrizzi F., Shoenfeld Y. Intravenous immunoglobulin treatment of lupus nephritis. Semin Arthritis Rheum. 2000 Apr;29(5):321–327. doi: 10.1016/s0049-0172(00)80018-9. [DOI] [PubMed] [Google Scholar]
  51. Lewis E. J., Hunsicker L. G., Lan S. P., Rohde R. D., Lachin J. M. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med. 1992 May 21;326(21):1373–1379. doi: 10.1056/NEJM199205213262101. [DOI] [PubMed] [Google Scholar]
  52. Lewis E. J., Schwartz M. M., Korbet S. M. Severe lupus nephritis: importance of re-evaluating the histologic classification and the approach to patient care. J Nephrol. 2001 Jul-Aug;14(4):223–227. [PubMed] [Google Scholar]
  53. Maloney D. G. Preclinical and phase I and II trials of rituximab. Semin Oncol. 1999 Oct;26(5 Suppl 14):74–78. [PubMed] [Google Scholar]
  54. Martinelli R., Pereira L. J., Santos E. S., Rocha H. Clinical effects of intermittent, intravenous cyclophosphamide in severe systemic lupus erythematosus. Nephron. 1996;74(2):313–317. doi: 10.1159/000189327. [DOI] [PubMed] [Google Scholar]
  55. Mok C. C., Ho C. T., Siu Y. P., Chan K. W., Kwan T. H., Lau C. S., Wong R. W., Au T. C. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis. 2001 Aug;38(2):256–264. doi: 10.1053/ajkd.2001.26084. [DOI] [PubMed] [Google Scholar]
  56. Mok C. C., Lau C. S., Wong R. W. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 1998 May;41(5):831–837. doi: 10.1002/1529-0131(199805)41:5<831::AID-ART9>3.0.CO;2-1. [DOI] [PubMed] [Google Scholar]
  57. Mok C. C., Wong R. W., Lau C. S. Lupus nephritis in Southern Chinese patients: clinicopathologic findings and long-term outcome. Am J Kidney Dis. 1999 Aug;34(2):315–323. doi: 10.1016/s0272-6386(99)70361-6. [DOI] [PubMed] [Google Scholar]
  58. Mok Chi Chiu, Ho Carmen Tze Kwan, Chan Kwok Wah, Lau Chak Sing, Wong Raymond Woon Sing. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum. 2002 Apr;46(4):1003–1013. doi: 10.1002/art.10138. [DOI] [PubMed] [Google Scholar]
  59. Mok Chi Chiu, Lai Kar Neng. Mycophenolate mofetil in lupus glomerulonephritis. Am J Kidney Dis. 2002 Sep;40(3):447–457. doi: 10.1053/ajkd.2002.34882. [DOI] [PubMed] [Google Scholar]
  60. Moroni G., Quaglini S., Maccario M., Banfi G., Ponticelli C. "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int. 1996 Dec;50(6):2047–2053. doi: 10.1038/ki.1996.528. [DOI] [PubMed] [Google Scholar]
  61. Najafi C. C., Korbet S. M., Lewis E. J., Schwartz M. M., Reichlin M., Evans J., Lupus Nephritis Collaborative Study Group Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int. 2001 Jun;59(6):2156–2163. doi: 10.1046/j.1523-1755.2001.00730.x. [DOI] [PubMed] [Google Scholar]
  62. Nossent H. C., Koldingsnes W. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis. Rheumatology (Oxford) 2000 Sep;39(9):969–974. doi: 10.1093/rheumatology/39.9.969. [DOI] [PubMed] [Google Scholar]
  63. Perrotta Silverio, Locatelli Franco, La Manna Angela, Cennamo Lucia, De Stefano Piero, Nobili Bruno. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol. 2002 Feb;116(2):465–467. [PubMed] [Google Scholar]
  64. Petri Michelle, Jones Richard J., Brodsky Robert A. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum. 2003 Jan;48(1):166–173. doi: 10.1002/art.10752. [DOI] [PubMed] [Google Scholar]
  65. Pfueller B., Wolbart K., Bruns A., Burmester G. R., Hiepe F. Successful treatment of patients with systemic lupus erythematosus by immunoadsorption with a C1q column: a pilot study. Arthritis Rheum. 2001 Aug;44(8):1962–1963. doi: 10.1002/1529-0131(200108)44:8<1962::AID-ART335>3.0.CO;2-R. [DOI] [PubMed] [Google Scholar]
  66. Radis C. D., Kahl L. E., Baker G. L., Wasko M. C., Cash J. M., Gallatin A., Stolzer B. L., Agarwal A. K., Medsger T. A., Jr, Kwoh C. K. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum. 1995 Aug;38(8):1120–1127. doi: 10.1002/art.1780380815. [DOI] [PubMed] [Google Scholar]
  67. Sesso R., Monteiro M., Sato E., Kirsztajn G., Silva L., Ajzen H. A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis. Lupus. 1994 Apr;3(2):107–112. doi: 10.1177/096120339400300209. [DOI] [PubMed] [Google Scholar]
  68. Shapira Y., Mor F., Friedler A., Wysenbeek A. J., Weinberger A. Antiproteinuric effect of captopril in a patient with lupus nephritis and intractable nephrotic syndrome. Ann Rheum Dis. 1990 Sep;49(9):725–727. doi: 10.1136/ard.49.9.725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Steinberg A. D., Decker J. L. A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis. Arthritis Rheum. 1974 Nov-Dec;17(6):923–937. doi: 10.1002/art.1780170602. [DOI] [PubMed] [Google Scholar]
  70. Steinberg A. D., Steinberg S. C. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum. 1991 Aug;34(8):945–950. doi: 10.1002/art.1780340803. [DOI] [PubMed] [Google Scholar]
  71. Takada K., Illei G. G., Boumpas D. T. Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus. 2001;10(3):154–161. doi: 10.1191/096120301671376017. [DOI] [PubMed] [Google Scholar]
  72. Tam L. S., Li E. K., Leung C. B., Wong K. C., Lai F. M., Wang A., Szeto C. C., Lui S. F. Long-term treatment of lupus nephritis with cyclosporin A. QJM. 1998 Aug;91(8):573–580. doi: 10.1093/qjmed/91.8.573. [DOI] [PubMed] [Google Scholar]
  73. Traynor A. E., Schroeder J., Rosa R. M., Cheng D., Stefka J., Mujais S., Baker S., Burt R. K. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet. 2000 Aug 26;356(9231):701–707. doi: 10.1016/S0140-6736(00)02627-1. [DOI] [PubMed] [Google Scholar]
  74. Valeri A., Radhakrishnan J., Estes D., D'Agati V., Kopelman R., Pernis A., Flis R., Pirani C., Appel G. B. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol. 1994 Aug;42(2):71–78. [PubMed] [Google Scholar]
  75. Wallace D. J., Goldfinger D., Pepkowitz S. H., Fichman M., Metzger A. L., Schroeder J. O., Euler H. H. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J Clin Apher. 1998;13(4):163–166. doi: 10.1002/(sici)1098-1101(1998)13:4<163::aid-jca4>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  76. Wallace Daniel J. Management of lupus erythematosus: recent insights. Curr Opin Rheumatol. 2002 May;14(3):212–219. doi: 10.1097/00002281-200205000-00003. [DOI] [PubMed] [Google Scholar]
  77. Wang C. L., Wang F., Bosco J. J. Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus. 1995 Feb;4(1):11–14. doi: 10.1177/096120339500400103. [DOI] [PubMed] [Google Scholar]
  78. Yang L. Y., Chen W. P., Lin C. Y. Lupus nephritis in children--a review of 167 patients. Pediatrics. 1994 Sep;94(3):335–340. [PubMed] [Google Scholar]
  79. Zimmerman R., Radhakrishnan J., Valeri A., Appel G. Advances in the treatment of lupus nephritis. Annu Rev Med. 2001;52:63–78. doi: 10.1146/annurev.med.52.1.63. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES